I-branching N-acetylglucosaminyltransferase regulates prostate cancer invasiveness by enhancing α5β1 integrin signaling

Jotaro Mikami,1,5 Yuko Tobisawa,1,2,5 Tohru Yoneyama,1 Shingo Hatakeyama,1 Kazuyuki Mori,1 Yasuhiro Hashimoto,3 Takuya Koie,1 Chikara Ohyama1,3 and Minoru Fukuda2,4

1Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki; 2Hirosaki University Graduate School of Medicine, Hirosaki; 3Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; 4Sanford Burnham Prebys Medical Discovery Institute, Tumor Microenvironment and Metastasis Program, NCI-Designated Cancer Center, La Jolla, California, USA

Key words
Cell migration, glycolipid, I-antigen, I-branching N-acetylglucosaminyltransferase, prostate cancer

Correspondence
Yuki Tobisawa, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, Japan.
Tel.: +81-172-39-5091; Fax: +81-172-39-5092;
E-mail: tobisawa@hirosaki-u.ac.jp

© 2015 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Cell surface carbohydrates are important for cell migration and invasion of prostate cancer (PCa). Accordingly, the I-branching N-acetylglucosaminyltransferase (GCNT2) converts linear I-antigen to I-branching glycan, and its expression is associated with breast cancer progression. In the present study, we identified relationships between GCNT2 expression and clinicopathological parameters in patients with PCa. Paraffin-embedded PCa specimens were immunohistochemically tested for GCNT2 expression, and the roles of GCNT2 in PCa progression were investigated using cell lines with high GCNT2 expression and low GCNT2 expression. GCNT2-positive cells were significantly lesser in organ-confined disease than in that with extra-capsular extensions, and GCNT2-negative tumors were associated with significantly better prostate-specific antigen-free survival compared with GCNT2-positive tumors. Subsequent functional studies revealed that knockdown of GCNT2 expression in PCa cell lines significantly inhibited cell migration and invasion. GCNT2 regulated the expression of cell surface I-antigen on the O-glycan and glycolipid. Moreover, I-antigen-bearing glycolipids were subject to α5β1 integrin–fibronectin mediated protein kinase B phosphorylation. In conclusion, GCNT2 expression is closely associated with invasive potential of PCa.
Materials and Methods

Materials. The O-glycosylation inhibitor BAG was purchased from Sigma-Aldrich (St. Louis, MO, USA). The N-glycosylation inhibitor TM was purchased from Wako Pure Chemical Company (Osaka, Japan). The glucosylceramide synthetase inhibitor PPMP was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antibodies used in this study are listed in Data S1.

Cells. The human PCa cell line LNCaP, DU145, and PC3 were purchased from ATCC (Rockville, MD, USA). Cells were maintained in RPMI-1640 medium (Wako Pure Chemical Company) containing 100 U/mL penicillin and 100 μg/mL streptomycin with 10% FBS (HyClone, Logan, UT, USA). Immortalized RWPE-1 prostate epithelial cells were also purchased from the ATCC. RWPE-1 was maintained in keratinocyte serum-free medium (Life Technologies, Carlsbad, CA, USA). DU145-derived GCNT2 knockdown cell lines were established by transfection of four different GCNT2siRNA vectors (Data S1). All cells were analyzed by short tandem repeat analysis (BEX, Tokyo, Japan).

Immunohistochemical analysis of PCa specimens. Between 2005 and 2011, 156 PCa patients were treated with radical prostatectomy at the Department of Urology, Hirosaki University Graduate School of Medicine (Hirosaki, Japan). Staging and grading of tumors and patient follow-up were previously described.(20) In brief, postoperative PSA levels were considered to be increased (PSA recurrence) if they were ≥0.2 ng/mL during two consecutive visits in a 1-month interval. Time zero was defined as the day of surgery. Patients with constantly detectable PSA levels (<0.001 ng/mL) after surgery were recorded as recurrences at time zero. Follow-up intervals were calculated from the date of surgery to the last recorded follow-up (median, 47.9 months; range, 26.7–79.6 months).(20) All tumor specimens after radical prostatectomy from these patients were formalin-fixed and embedded in paraffin. Deparaffinized specimens were incubated with the rabbit anti-human GCNT2 polyclonal Ab (1:200, HPA026776; Sigma) followed by incubation with HRP-conjugated goat anti-mouse/ rabbit IgG antibody (Dako, Tokyo, Japan). Based on the staining status of Golgi apparatus, specimens with 10% or more positive cancer cells were judged as GCNT2 positive. Informed consent was obtained from all patients prior to participation in this study. The ethics committee of Hirosaki University approved the study protocol, and the study was car-

Fig. 1. I-branching N-acetylgalactosaminyltransferase (GCNT2) expression correlates with prostate cancer progression. (a) Biosynthetic pathways for I-antigen. (b) Expression level of GCNT2 was determined using quantitative PCR analysis. (c) Prostate cancer specimens were stained with an anti-GCNT2 antibody followed by staining with an HRP-conjugated secondary antibody. Counterstaining was carried out using H&E. GCNT2-positive cancer cells are indicated in brown. (d) Prostate-specific antigen (PSA)-free survival periods were compared between GCNT2-positive and GCNT2-negative specimens, and survival analysis was carried out using Kaplan-Meier curves. Scale bar = 200 μm.
ried out in accordance with the ethical standards of the Declaration of Helsinki.

**Determination of GCNT2 expression in prostate cancer cell lines using quantitative real-time PCR.** Total RNA was isolated using Isogen II reagent, and then qPCR analyses were carried out using GeneAce SYBR qPCR Mix + No ROX (Nippon Gene, Tokyo, Japan) according to the manufacturer’s instructions. Primer sets are listed in Table S1. Gene expression levels were normalized to that of human GAPDH.

**Cell proliferation, migration, and invasion assays.** In vitro cell proliferation assays were carried out as described previously. In vitro cell migration and invasion assays were carried out using Boyden chambers as described previously.

The numbers of cells on the lower side were counted in triplicate using a Hybrid Cell Counting System (Keyence, Osaka, Japan).

**Flow cytometry.** Cells (1 × 10⁶) were incubated with or without primary antibody in 100 µL of 1% BSA–PBS for 30 min on ice followed by the incubation with fluorescence-conjugated isotype-specific secondary antibodies.

**Immunocytochemical analysis of I-antigen presentation on PCa cells.** Cells were cultured to 80% confluence on glass slides and were treated with 0.6% DMSO, 0.2 µg/mL TM, and 20 µg/mL PPMP on glass slides for 48 h. Immunocytochemical analysis was carried out as described previously.

**Fibronectin adhesion and spreading assays.** Adhesion assays and spreading assays were carried out using fibronectin-coated dishes as previously described.

**Immunoprecipitation.** The αS1 integrin heterodimer complex levels were determined in lysates from DU145-derived cells. Cells were incubated with 2 µg/mL rabbit monoclonal anti-αS1 integrin antibody (EPR7854; Abcam, Cambridge, MA, USA) or mouse monoclonal anti-β1 integrin antibody (P5D2; Abcam) and were then incubated with protein G Dynabeads (Life Technologies). Immune complexes were eluted from Dynabeads using 3× Laemmli SDS-PAGE sample buffer.

**Western blotting.** Total cell lysates were prepared using 1% Igepal CA-630 (Sigma) containing protease inhibitor cocktail (Roche, Basel, Switzerland). Briefly, samples were separated using 4–15% SDS-PAGE gradient gels (Bio-Rad, Hercules, CA, USA) and were then transferred onto PVDF membranes. Western blot analysis was carried out using specific primary antibodies and HRP-conjugated secondary antibodies. After incubation with secondary antibodies, all samples were enzymatically visualized using Novex ECL Chemiluminescent Substrate Reagent Kits (Life Technologies) and a ChemiDoc XRS+ System (Bio-Rad).

**Focal adhesion kinase and AKT stimulation on fibronectin.** DU145-derived cell lines were cultured in the absence of serum for 48 h and were then detached using an enzyme-free cell dissociation solution (Millipore, Temecula, CA, USA). Subsequently, 1 × 10⁵ cells were seeded on 20 µg/mL fibronectin-coated 6-well plates. After incubation for 5, 10, and 20 min, cells were washed once in PBS and were lysed using 1% Igepal CA-630 solution containing protease inhibitor cocktail and PhosStop (Roche).

**Inhibition assays.** Cells were pretreated with 20 µg/mL anti-αS integrin antibody (NK1-SAM-1), 10 µg/mL anti-β1 integrin antibody (P5D2), or 20 µg/mL corresponding control isotype antibody at on ice for 30 min and migration and fibronectin stimulation assays were carried out.

Cells were treated with the AKT inhibitor VIII (10 µM; Cayman Chemical Company, Ann Arbor, MI, USA) or with DMSO, and migration assays were carried out. In separate experiments, cells were cultured with the BAG (2 mM), PPMP (20 µg/mL), or DMSO for 48 h and were then subjected to migration and fibronectin stimulation assays. In RGD peptide blocking assay, cells were pretreated with 100, 200, 400, or 800 µM RGD peptide (sc-201176; Santa Cruz) or vehicle control on ice for 30 min and fibronectin stimulation assays were carried out.

**Statistical analysis.** Associations of GCNT2 status with clinical and histopathological parameters were analyzed using χ²-tests. Prostate-specific antigen-free survival was evaluated using Kaplan–Meier curves, and differences between groups were assessed using the log–rank test. All statistical analyses were carried out using srsx 21.0 software (SPSS, Chicago, IL, USA). Multivariate analysis of in this study used Cox proportional hazards regression analysis to test the association of GCNT2 status with other clinical and pathological parameters, including patient age, initial PSA, clinical stage, biopsy Gleason score, post-operation Gleason score, pathological stage, margin status, and perineural invasion for the prediction of PSA recurrence.

**Results**

**Expression of GCNT2 in PCa positively correlates with cancer invasion and PSA recurrence.** To confirm that GCNT2 expression correlates with PCa aggressiveness, expression levels of three isoforms of GCNT2 were determined in PCa cell lines using qPCR. A transcript variant (isof orm A) of GCNT2 was the major isoform expressed in PCa cell lines. Whereas high expression of GCNT2 was observed in the highly invasive PCa cell lines DU145 and PC3, low-level expression of GCNT2 was observed in the poorly invasive LNCaP cell line (Fig. 1b). This result suggested that the high expression of GCNT2 correlates with invasive characteristics in PCa cell lines. To evaluate the role of GCNT2 in PCa aggressiveness, PCa specimens were immunohistochemically analyzed using a rabbit anti-GCNT2 polyclonal antibody. In these experiments, GCNT2 expression was detected in a partially healthy prostate gland and was highly expressed in some PCa cells (Fig. 1c). No significant differences in clinical parameters were observed between GCNT2-positive and GCNT2-negative PCa specimens from 156 patients (Table S2). However, >80% of tumor specimens had extraprostatic extensions (pT3 and pT4) that

| Table 1. Cox proportional hazards model for predicting prostate-specific antigen (PSA)-free survival |
|-----------------------------------------------|
| Multivariate analysis | P-value | Exp (B) | 95.0% CI |
|-----------------------------------------------|
| Age | 0.759 | 1.012 | 0.940 | 1.089 |
| iPSA | 0.022 | 1.065 | 1.009 | 1.123 |
| ≥T2 | 0.920 | 1.043 | 0.458 | 2.374 |
| Biopsy GS | 0.076 | 2.622 | 0.903 | 7.611 |
| Post-op GS | 0.701 | 0.819 | 0.295 | 2.276 |
| ≥T3 | 0.446 | 1.534 | 0.510 | 4.612 |
| Margin status | 0.027 | 1.034 | 0.015 | 0.253 |
| Perineural invasion | 0.822 | 1.121 | 0.413 | 3.041 |
| GCNT2 status | 0.032 | 9.021 | 1.203 | 67.630 |

†Pretreatment with PSA. §Extra-capsular extension. ¶Cancer presence at the resected margin. CI, confidence interval; Exp (B), odds ratio; GCNT2, 1-bran ching N-acetylgalactosaminyltransferase; GS, Gleason score.
Fig. 2. I-branching N-acetylgalactosaminyltransferase (GCNT2) expression controls prostate cancer cell invasion. (a) Messenger RNA expression of GCNT2 was determined in DU145 cells using quantitative PCR. GCNT2 expression levels were normalized to those of human G3PDH. Clone 3 and Clone 4 (DU145GCNT2KD3 and DU145GCNT2KD4) showed >70% inhibition of GCNT2 expression. (b) Protein expression of GCNT2 was determined in DU145-derived cells using Western blotting. The GCNT2 expression level was lower in DU145GCNT2KD3 and 4 than in DU145NC. (c) In vitro cell proliferation was similar in DU145GCNT2KD3 and 4 cells at day 7, and strongly reduced cell migration (d) and invasion (e) was observed in Transwell assays. Assays were carried out in triplicate. *P < 0.05.

Fig. 3. I-branching N-acetylgalactosaminyltransferase (GCNT2) expression regulates I-antigen presentation on prostate cancer cells. Cell surface I-antigen expression was determined using flow cytometry (FC) and immunocytochemistry with anti-I-antigen human antisera (AS). (a) DU145GCNT2KD3 and DU145GCNT2KD4 showed decreased cell surface I-antigen expression in FC analyses. (b) DU145NC and DU145GCNT2KD4 cells were cultured on glass slides and were stained with anti-I-antigen human antisera or the human IgM isotype control. Brown indicates I-antigen expression; blue indicates nuclear staining. DU145GCNT2KD4 cells had strongly reduced I-antigen expression. DU145 cells were cultured with benzyl-α-GalNAc (BAG), tunycamycin (TM), or DL-threo-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol hydrochloride (PPMP) for 48 h. I-antigen expression was determined using immunocytochemistry (c) and FC (d). I-antigen expression was significantly reduced in BAG-treated cells and PPMP-treated cells. TM-treated cells had no effect on I-antigen presentation. Co-treatment with BAG and PPMP strongly reduced I-antigen expression compared with either treatment alone. Population comparison was carried out using Flowjo software. Assays were carried out in triplicate. (e) Integrin expression was determined using FC, and expression of α5 and β1 integrins was similar in DU145NC and GCNT2 knockdown cell lines. NS, not significant; pAb, polyclonal antibody. Scale bar = 200 μm.
(a) Flow cytometry analysis of DU145NC and DU145GCNT2KD4 cells with and without antisera.

(b) Immunohistochemical staining of DU145NC cells with isotype control and anti-I-antigen.

(c) Immunohistochemical staining of DU145NC cells with anti-I-antigen and additional treatments: + BAG, + TM, + PPMP.

(d) Flow cytometry analysis of BAG, PPMP, BAG+PPMP, and TM treatments with and without antisera on DU145NC cells.

(e) Comparisons of relative intensity of DU145NC and DU145GCNT2KD4 cells with and without antisera treatments.

Integrin \( \alpha_5 \) and Integrin \( \beta_1 \) expression levels are shown with statistical significance indicated by \( P < 0.001 \), \( P < 0.05 \), and NS (not significant).
expressed GCNT2 in accordance with pathological parameters (Table S3), and GCNT2-positive patients were at significantly higher risk of PSA recurrence after radical prostatectomy (Fig. 1d). Moreover, nodal metastatic PCa cells also expressed GCNT2 (Fig. S1). According to multivariate analyses, PSA levels, margin status, and GCNT2 expression in tumors were independent risk factors for PSA recurrence (Table 1). These results indicate that GCNT2 expression correlates with PCa invasion and progression.

**GCNT2 regulates PCa cell migration and invasion.** To investigate the role of GCNT2 expression in PCa cells, we established GCNT2 knockdown DU145 cell lines. In subsequent qPCR analyses and Western blotting, clone 3 and clone 4 showed >70% inhibition of GCNT2 expression (Fig. 2a,b). Although GCNT2 knockdown significantly inhibited cell proliferation at day 3 in clone 3 (DU145GCNT2KD3), total cell numbers at day 7 did not differ between siControl (DU145NC), DU145GCNT2KD3, and clone 4 (DU145GCNT2KD4) cells (Fig. 2c). These results suggest that GCNT2 expression is not critical for cell proliferation in vitro. In subsequent experiments, the effects of GCNT2 expression were examined using migration and invasion assays in DU145NC, GCNT2KD3, and GCNT2KD4 cells using a Transwell system. In comparisons with DU145NC cells, migration and invasion were strongly inhibited in GCNT2 knockdown cell lines (Fig. 2d,e). In further experiments, GCNT2 expression was transiently inhibited using siRNA transfection in PC3 cells and resulted in decreased invasion potential (Fig. S2a). Moreover, wound healing assays showed significantly decreased surface coverage rates in GCNT2 knockdown cell lines compared with that in DU145NC cells (Fig. S2b). In a previous study, high expression of GCNT2 was associated with EMT and accelerated cell invasion in breast cancers. In agreement, we investigated the effects of GCNT2 on cell surface glycan structures (Fig. 1a). Specifically, GCNT2-expressing PCa cell lines showed pronounced cell surface presentation of I-antigen (Fig. S3a,b). In contrast, GCNT2 knockdown cells had limited I-antigen presentation on cell surfaces (Fig. 3a,b). GCNT2 reportedly acts on O-glycans, N-glycans, and glycolipids to form GlcNAc-Gal branches (Fig. 1a). Accordingly, after treatment of DU145NC cells with the inhibitors BAG or PPMP, significantly decreased I-antigen expression was observed. Moreover, co-treatment with BAG and PPMP led to greater inhibition of I-antigen presentation than individual treatments (Fig. 3d). In contrast, treatment with TM did not decrease I-antigen presentation on cell surfaces (Fig. 3c,d). Treatment with these inhibitors decreased each glycan on the cell surface (Fig. S4), suggesting that I-antigens were formed on O-glycan and glycolipid molecules on PCa cell surfaces.

**I-antigen enhances α5β1 integrin signaling.** Integrin is a well-known heterodimeric receptor of the ECM and has reported roles in cell adhesion. The major stromal ECM motility factor fibronectin has been shown to interact with the integrin α5β1 heterodimer in a glycan-structure dependent manner. In the present experiments, α5 integrin and β1 integrin were expressed at similar levels in DU145NC and GCNT2 knockdown cells (Fig. 3e). Thus, to confirm the role of I-antigen in cell–ECM interactions, adhesion and spreading assays were carried out using DU145 cell lines on fibronectin-coated plates. Although adhesion on fibronectin did not differ between DU145NC and DU145GCNT2KD4 cells, significantly fewer DU145GCNT2KD4 cells showed spreading activity (Fig. 4a,b). Integrin–ECM interactions that mediate outside–inside signals play important roles in cell spreading and migration. Moreover, abnormal heterodimeric forms of these molecules have been shown to inhibit integrin-mediated signaling. However, heterodimeric forms of α5β1 integrin did not differ between GCNT2 knockdown and DU145NC cells (Fig. 4c). In previous studies, FAK and PI3K/AKT are reported downstream targets of integrin-mediated signaling. Although FAK phosphorylation at tyrosine 397 (p-Y397) was not affected by GCNT2 expression on fibronectin-coated plates, AKT phosphorylation at serine 473 (p-S473) was significantly less in DU145GCNT2KD4 cells than in DU145NC cells (Fig. 4d). Moreover, AKT p-S473 was inhibited by antibody blocking and RGD peptide of the fibronectin-integrin interaction (Fig. 4e,f). Thus, we confirmed that I-antigens enhance integrin-mediated PI3K/AKT signaling.

**I-antigens support α5β1 integrin–fibronectin-induced cell migration.** To demonstrate the roles of I-antigens, cell migration assays were carried out after treatment of DU145 cells with various inhibitors. In these experiments, function-blocking antibodies against α5 integrin and β1 integrin strongly inhibited DU145NC and DU145GCNT2KD4 cell migration (Fig. 5a). Moreover, the AKT phosphorylation inhibitor had high efficacy in DU145 cells without causing cytotoxicity (Fig. 5a,b). Although numbers of migrant cells were significantly fewer among DU145NC cells in which AKT is strongly activated (Fig. 5c,d), numbers at day 7 did not differ between GCNT2 knockdown and DU145NC cells (Fig. 5a). In addition, cell viability was >90% after BAG and PPMP treatments (Fig. 5c,d), indicating that O-glycans carrying I-antigens support cell migration, and that glycolipids carrying I-antigens play important roles in integrin–fibronectin-mediated PI3K/AKT activation and cell migration.

**Discussion**

This study indicates that highly metastatic PCa cell lines express GCNT2 at high levels. On the basis of immunohistochemical analyses of radical prostatectomy specimens, GCNT2 expression on PCa cell surfaces closely correlated with extracapsular extensions of PCa. It is also noteworthy that patients with GCNT2-negative PCa showed better PSA-free survival compared with patients with GCNT2-positive tumors (Fig. 1). Moreover, multivariate analysis revealed that GCNT2 is an independent predictor for PSA recurrence (Table 1). Subsequent experiments also indicated strong correlations between GCNT2 expression and malignant potential of PCa.
Fig. 4. I-antigen regulates cell spread and α5β1 integrin–fibronectin interactions that are mediated by protein kinase B (AKT) phosphorylation in DU145NC and DU145GCNT2KD4 cells. Cell adhesion and spreading on fibronectin (FN) was examined by harvesting cells after a 30 min of culture on fibronectin-coated 96-well plates (a). DU145NC and DU145GCNT2KD4 cells showed no significant differences in adhesion potential. (b) Cells were harvested from fibronectin-coated glass slides after 30 min of incubation, and spreading cells were visualized using crystal violet solution. Percentages of spreading cells were significantly lower in DU145GCNT2KD4 cells than in DU145NC cells. (c) Cell lysates from DU145 cells were immunoprecipitated using anti-integrin α5 or β1 antibodies, and heterodimers were detected. L-branching N-acetylglucosaminyltransferase (GCNT2) expression had no effect on heterodimerization of α5β1 integrin. (d) Focal adhesion kinase (FAK) and AKT are downstream targets of integrin signaling. FAK phosphorylation at tyrosine 397 (p-Y397) was similar in DU145NC and DU145GCNT2KD4 after integrin–fibronectin interactions. In contrast, AKT phosphorylation at serine 473 (p-S473) was strongly inhibited by GCNT2 knockdown in DU145 cells. (e) A functional blocking antibody against α5 and β1 integrins inhibited α5β1 integrin–fibronectin interactions. Pretreatment of DU145NC and DU145GCNT2KD4 cells with anti-integrin α5 or β1 led to lower FAK p-Y397 and AKT p-S473 levels compared with those after pretreatment with IgG isotype control. (f) Pretreatment of DU145NC cells with RGD peptide (100, 200, 400, or 800 μM) inhibited FAK p-Y397 and AKT p-S473 in a concentration-dependent manner. IB, immunoblotting; IP, immunoprecipitation; NS, not significant; t-FAK, total-FAK; t-AKT, total-AKT.
Integrin–ECM-mediated signaling is reportedly central to solid tumor locomotion, \(^{29,30}\) and integrin function is reportedly regulated by glycan structure. \(^{33}\) Integrin \(\alpha_5\beta_1\) is a well-known fibronectin receptor and its binding function is regulated by N-glycan. Moreover, depletion of N-glycan from \(\alpha_5\beta_1\) integrin by \(N\)-glycosidase F inhibited \(\alpha_5\beta_1\) integrin–fibronectin interactions, \(^{38}\) and cell motility was positively associated with the formation of MGAT5-mediated GlcNAcβ1-6 branching N-glycans. \(^{22}\) Inhibition of \(\alpha\)mannosidase I by 1-deoxymannojirimycin in fibroblasts led to the formation of high mannose type N-glycan, and although immature \(\alpha_5\beta_1\) integrin was overexpressed on cell surfaces, the immature form strongly inhibited fibronectin binding affinity. \(^{27}\) GCNT2 also transformed GlcNAc β1-6 residues to galactose and formed the 1-antigen on N-glycans (Fig. 1). \(^{12}\) In the present study, we showed that 1-antigens predominantly carried O-glycans and glycolipids (Fig. 3), and were not affected by \(\alpha_5\beta_1\) integrin heterodimerization and fibronectin binding affinity. Knockdown of GCNT2 also led to similar \(\alpha_5\beta_1\) integrin expression levels, suggesting that GCNT2-mediated branched-form 1-antigen indirectly regulates \(\alpha_5\beta_1\) integrin function in PCa cells.

Previous studies showed associations between glycolipids and malignant potential of melanomas, \(^{34}\) breast cancers, \(^{35,36}\) and prostate cancers. \(^{37}\) In accordance, glycolipids were expressed on various cell surfaces, and their glycan structures were modified by several glycosyltransferases. Moreover, these glycolipids regulated not only cell–cell interactions but also regulated cell adhesion and migration by glycolipid–tetraspanin or glycolipid–caveola interactions. \(^{36}\) Glycophosphingolipid GM3 (NeuAcx2-3Galβ1-4Glcβ1-Cer) was also predominantly expressed at cell adhesion cites and inhibited cell migration. In a previous study of bladder carcinomas, high expression of GM3 blocked integrin and tetraspanin interactions and inhibited Src kinase signaling. \(^{40}\) In the present study, GCNT2 had the potential to modify glycolipids, and its inhibition strongly reduced cell migration (Fig. 2). In addition, GCNT2 knockdown PCa cells showed strongly reduced \(\alpha_5\beta_1\) integrin–fibronectin-mediated AKT phosphorylation (Fig. 4). Previously, AKT phosphorylation was regulated by integrin-linked kinase, which is a known downstream target of integrin-activated Src kinase. \(^{33,41}\) Moreover, effects of AKT activation on proliferation, survival, and migration have been reported \(^{42}\) and suggest that glycolipid-bearing I-antigens stabilize integrin-mediated signaling and/or integrin/tetraspanin-mediated Src kinase activation. Because inhibition of AKT phosphorylation inhibited PCa cell migration, glycolipid-bearing I-antigens enhance AKT phosphorylation and cell migration.

To establish a new diagnostic marker and therapeutic target, Carroll et al. \(^{43}\) immunized mice against the androgen-independent prostate cancer cell line PC3 and established a mAb against F77. Subsequently, high expression of the F77 antigen was shown in androgen-independent prostate cancer cell lines (PC3 and DU145), which had reduced cell proliferation in vitro and in vivo in the presence of the F77 mAb. In a subsequent study,
the F77 antigen was shown to be carried by glycolipids.\(^{44}\)
Moreover, a recent study showed that the F77 mAb recognized the F77 antigen was shown to be carried by glycolipids.\(^{44}\)

Although the mechanisms of GCNT2-mediated cancer progression remain poorly understood, the present experiments indicate that GCNT2-formed I-antigens are predictive of the malignant potential of PCA cells. However, further research is necessary to determine the utility of GCNT2 as a therapeutic target and biomarker for PCA.

Acknowledgments
The authors thank Dr. Shigemi Tsuboi and Ms. Sayaka Yamada for useful discussions and technical support. This work was supported by the Japan Society for the Promotion of Science (KAKENHI Grant Nos. 24791631 and 15K10569 to Y.T. and 15H02563 to C.O.), the Hirosaki University Grant for Exploratory Research by Young Scientists (to Y.T.), and a National Institutes of Health Grant (U01 CA168925 to M.F.).

Disclosure Statement
The authors have no conflict of interest.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| AKT          | protein kinase B |
| BAG          | benzyl-\(\beta\)-GalNAc |
| EMT          | epithelial–mesenchymal transition |
| FAK          | focal adhesion kinase |
| GCNT2        | I-branching N-acetylgalcosaminytransferase |
| GlcNAc       | N-acetylgalcosamine |
| MGAT5        | mannosyl (alpha-1,6)-glycoprotein beta-1,6-N-acetylgalcosaminytransferase |
| PI3K         | phosphoinositide 3-kinase |
| PPM          | DL-threo-1-phenyl-2-palmitoylaminio-3-morpholinol-1-propanol hydrochloride |
| PSA          | prostate-specific antigen |
| qPCR         | quantitative PCR |
| TM           | tunicamycin |

References
1. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingolipid metabolism. Cancer Res 1996; 56: 5309–18.
2. Fukuda M. Possible roles of tumor-associated carbohydrate antigens. Cancer Res 1996; 56: 2237–44.
3. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1999; 1473: 21–34.
4. Stenå A, Studer UE. Outcome of patients with untreated cancer of the prostate. Eur Urol 1993; 24: 1–6.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30.
6. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Patterns. IARC CancerBase No. 11, 2013; 468.
7. Baade PD, Youlden DR, Cramb SM, Dunn J, Gardiner RA. Epidemiology of cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374–403.
8. Baade PD, Youlend DR, Cramb SM, Dunn J, Gardner RA. Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int 2013; 1: 47–58.
9. Catalona WJ. Management of cancer of the prostate. New England J Med 1994; 331: 996–1004.
10. Drabik A, Cioczkry-Zwiezbek D, Dulsinka-Litewka J et al. A comparative study of glycoproteomes in androgen-sensitive and -independent prostate cancer cell lines. Mol Cell Biochem 2014; 386: 189–98.
11. Chen GY, Kurosawa N, Muramatsu T. A novel variant form of murine beta-1, 6-N-acetylgalcosaminytransferase forming branches in poly-N-acetyllactosaminies. Glycobiology 2000; 10: 1001–11.
12. Inaba N, Hiruma T, Togayachi A et al. A novel I-branching beta-1,6-N-acetylgalcosaminytransferase involved in human blood group I antigen expression. Blood 2003; 101: 2870–6.
13. Bienhuzen MF, Mattee MG, Fukuda M. Expression of the developmenta1 I antigen by a cloned human cDNA encoding a member of a beta-1,6-N-acetylgalcosaminytransferase gene family. Genes Dev 1993; 7: 468–78.
14. Wieland AS, Unger LJ, Cohen L, Feldman J. Type-specific cold auto-antibodies as a cause of acquired hemolytic anemia and hemolytic transfusion reactions: biologic test with bovine red cells. Ann Intern Med 1956; 44: 221–40.
15. Muramatsu H, Kusano T, Sato M, Oda Y, Kobori K, Muramatsu T. Embryonic stem cells deficient in I beta-1,6-N-acetylgalcosaminytransferase exhibit reduced expression of embryoglycans and the loss of a Lewis X antigen. EMBO J 1999; 18: 1516–25.
16. Tsuji K, Chang PL, Feng TH, Chung LC, Sung HC, Jiang HH. Evaluating the function of matrapsite and N-acetylgalcosaminytransferase V in prostate cancer metastasis. Anticancer Res 2008; 28: 1993–9.
17. Higasawa S, Ohyama C, Takahashi T et al. Expression of core 2 beta-1,6-N-acetylgalcosaminytransferase facilitates prostate cancer progression. Glyco-biology 2005; 15: 1016–24.
18. Hatakeyama S, Kyan A, Yamamoto H et al. Core 2 N-acetylgalcosaminytransferase-1 expression induces aggressive potential of testicular germ cell tumor. Int J Cancer 2010; 127: 1052–9.
19. Zhang H, Meng F, Wu S et al. Engagement of I-branching (beta)-1, 6-N-acetylgalcosaminytransferase 2 in breast cancer metastasis and TGF-(beta) signaling. Cancer Res 2011; 71: 4846–56.
20. Kojima Y, Yoneyama T, Hatakeyama S et al. Detection of Core2 beta-1,6-N-acetylgalcosaminytransferase in Post-Digital Rectal Examination Urine Is a Reliable Indicator for Extracapsular Extension of Prostate Cancer. PLoS ONE 2015; 10: e0138520.
21. Nonaka M, Fukuda MN, Gao C et al. Determination of carbohydrate structure recognized by prostate-specific F77 monoclonal antibody through expression analysis of glycosyltransferase genes. J Biol Chem 2014; 289: 16478–86.
22. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initia-
tion and progression. Nature 2004; 432: 332–7.
23. Xiao H, Lee I, Kamar M, Akiyama SK, Pierce M. Aberrant N-glycosylation of betal integrin genes reduced alpha5beta1 integrin clustering and stimu-
lates cell migration. Cancer Res 2002; 62: 6837–47.
24. Bhovmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initia-
tion and progression. Nature 2004; 432: 332–7.
25. Bao X, Kobayashi M, Hatakeyama S et al. Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylgalcosaminy-
transferase. Proc Natl Acad Sci USA 2009; 106: 12109–14.
26. Tsuboi S, Sutoh M, Hatakeyama S et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J 2011; 30: 3173–85.
27. Giancotti FG, Ruoslahti E. Integrin signaling. Nature 1997; 386: 541–3.
28. Isaji T, Su J, Nishiuichi R et al. Introduction of bisecting GlcNAc into integ-
rin alpha5beta1 reduces ligand binding and down-regulates cell adhesion and cell migration. J Biol Chem 2004; 279: 19747–54.
29. Zheng M, Fang H, Hakomori S. Functional role of N-glycosylation in alpha 5 integrin receptor. De-N-glycosylation induces dissociation or altered association of alpha 5 and beta 1 subunits and concomitant loss of fibronec-
tin binding activity. J Biol Chem 1994; 269: 12325–31.
30. Yamada KM, Geiger B. Molecular interactions in cell adhesion complexes. Curr Opin Cell Biol 1997; 9: 76–85.
31. Hynes RO. Integrins: a family of cell surface receptors. Cell 1987; 48: 549–54.
32. Isaji T, Sato Y, Zhao Y et al. N-glycosylation of the beta-propeller domain of the integrin alpha5 subunit is essential for alpha5beta1 heterodimerization, expression on the cell surface, and its biological function. J Biol Chem 2006; 281: 33258–67.
33. Lee SH, Hatakeyama S, Yu SY et al. Core3 O-glycan synthase suppresses tumor formation and metastasis of prostate carcinoma PC3 and LNCaP cells.
through down-regulation of alpha2beta1 integrin complex. J Biol Chem 2009; 284: 17157–69.

33 Wu C, Dedhar S. Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol 2001; 155: 505–10.

34 Hamamura K, Furukawa K, Hayashi T et al. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc Natl Acad Sci USA 2005; 102: 11041–6.

35 Gu Y, Zhang J, Mi W et al. Silencing of GM3 synthase suppresses lung metastasis of murine breast cancer cells. Breast Cancer Res 2008; 10: R1.

36 Liang YJ, Ding Y, Levery SB, Lobaton M, Handa K, Hakomori SI. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci USA 2013; 110: 4968–73.

37 Shimada S, Ito A, Kawasaki Y et al. Ganglioside disialosyl globopentaosylceramide is an independent predictor of PSA recurrence-free survival following radical prostatectomy. Prostate Cancer and Prostatic Dis 2014; 17: 199–205.

38 Hakomori S. Carbohydrate-to-carbohydrate interaction, through glycosynapse, as a basis of cell recognition and membrane organization. Glycoconj J 2004; 21: 125–37.

39 Hakomori SI. Structure and function of glycosphingolipids and sphingolipids: recollections and future trends. Biochim Biophys Acta 2008; 1780: 325–46.

40 Hakomori SI. Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility. FEBS Lett 2010; 584: 1901–6.

41 Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 2013; 1833: 3481–98.

42 Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29–86.

43 Carroll AM, Zalutsky M, Schatten S et al. Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen. Clin Immunol Immunopathol 1984; 33: 268–81.

44 Zhang G, Zhang H, Wang Q et al. Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker. Proc Natl Acad Sci USA 2010; 107: 732–7.

45 Gao C, Liu Y, Zhang H et al. Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array. J Biol Chem 2014; 289: 16462–77.

Supporting Information

Additional supporting information may be found in the online version of this article:

Fig. S1. Nodal metastatic prostate cancer expresses I-branching N-acetylgalcosaminyltransferase (GCNT2).

Fig. S2. I-branching N-acetylgalcosaminyltransferase (GCNT2) expression regulates prostate cancer cell migration and invasion without affecting epithelial–mesenchymal transition.

Fig. S3. I-antigen expression on the cell surface of I-branching N-acetylgalcosaminyltransferase (GCNT2)-expressing prostate cancer cell lines.

Fig. S4. Treatment with glycosylation inhibitor decreases presentation of O-glycan, N-glycan, and glycolipid on prostate cancer cell surface.

Fig. S5. Protein kinase B (AKT) inhibitor, O-glycosylation inhibitor, and glucosylceramide synthetase inhibitor had no effects on cell viability during assays.

Table S1 Primers used in this study.

Table S2 I-branching N-acetylgalcosaminyltransferase status and patient data.

Table S3 I-branching N-acetylgalcosaminyltransferase status and pathological parameters.

Data S1. Supplementary materials and methods.